Virtual Meetings 2023

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes

For an up-to-date schedule of upcoming sessions in this series, please click here.


Naval Daver, MD
Director, Leukemia Research Alliance Program
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Gail J Roboz, MD
Director, Clinical and Translational Leukemia Programs
Professor of Medicine
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

Richard M Stone, MD
Lunder Family Chair in Leukemia
Chief of Staff
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Neil Love, MD
Research To Practice

These activities are supported by educational grants from Daiichi Sankyo Inc, Gilead Sciences Inc, and Taiho Oncology Inc.


Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A
Topics to Be Discussed
  • Selection of Initial Therapy for Patients with Acute Myeloid Leukemia (AML) without a Targetable Mutation
  • Optimizing the Use of Targeted Therapy for Patients with AML and FLT3 or IDH Mutations
  • Other Novel Approaches in the Management of AML
  • Recent Advances in the Management of Myelodysplastic Syndromes

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, and other healthcare providers involved in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Learning Objectives

At the conclusion of this activity, participants should be able to
  • Evaluate the importance of age, performance status and other biological and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
  • Appreciate published clinical research findings with venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
  • Reflect on available research with approved FLT3 inhibitors, and use this information to guide clinical care for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Develop an understanding of published data with and the current role of IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation, and incorporate these agents into current management algorithms.
  • Recall published research data with promising investigational agents and strategies under evaluation for AML, and counsel appropriately selected patients regarding clinical trial enrollment.
  • Recognize the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for lower- and higher-risk myelodysplastic syndromes (MDS).
  • Recollect mechanisms of action of, available data with and ongoing studies evaluating novel agents and approaches for lower- and higher-risk MDS, and counsel appropriately selected patients about the potential benefits of clinical trial participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Daver Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, Astellas, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Menarini Group, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Shattuck Labs, Stemline Therapeutics Inc, Syndax Pharmaceuticals Inc, Trillium Therapeutics Inc; Contracted Research:  AbbVie Inc, Amgen Inc, Astellas, Bristol Myers Squibb, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Hanmi Pharmaceutical, ImmunoGen Inc, Kite, A Gilead Company, NovImmune SA, Pfizer Inc, Servier Pharmaceuticals LLC, Trillium Therapeutics Inc, Trovagene. Dr Stone Consulting Agreements: AbbVie Inc, Amgen Inc, Aptevo Therapeutics, AvenCell, BerGenBio ASA, Bristol Myers Squibb, Celularity, CTI BioPharma Corp, DAVA Oncology, GSK, Hemavant, Jazz Pharmaceuticals Inc, Kura Oncology, Lava Therapeutics, Ligand Pharmaceuticals, Redona Therapeutics, Rigel Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Aptevo Therapeutics, Epizyme Inc, Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc.

MODERATORDr Love: Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from Daiichi Sankyo Inc, Gilead Sciences Inc, and Taiho Oncology Inc.